A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.

Trial Details

NCT ID

NCT07258979

Phase

PHASE1 / PHASE2

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Status

RECRUITING

Cancer Type

Nasopharyngeal Head and Neck Cancer

Interventions

YL201
Toripalimab
Cisplatin

Locations (sample)

Chongqing, Chongqing Municipality, China|29.56026,106.55771
Fuzhou, Fujian, China|26.06139,119.30611
Xiamen, Fujian, China|24.47979,118.08187
Zhangzhou, Fujian, China|24.51333,117.65556
Dongguan, Guangdong, China|23.01797,113.74866

Key Eligibility Criteria

Voluntarily sign a written informed consent form (ICF).
Aged ≥18 years and ≤75 years, male or female.
ECOG performance status score of 0 or 1.
Life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →